All In Biotech

Drug Trial Radar · NCT03771898

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

May 13, 2019

Primary completion

Mar 8, 2023

Study completion May 6, 2026

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Dec 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 72 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to determine if SHP611 given by injection into the spinal fluid that surrounds the brain and spinal cord (intrathecal; IT) prolongs the time for children with Metachromatic Leukodystrophy (MLD) to retain the ability to move from place to place. Other aims of the study are to determine the effects of intrathecal administration of SHP611 on movement and speech functions and to learn how well SHP611 injected in the spinal fluid that surrounds the brain and spinal cord is tolerated. Study participants will receive SHP611 for about 2 years with the possibility of an extended treatment period.

Conditions

  • Metachromatic Leukodystrophy (MLD)

Interventions

  • SHP611Drug

    Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Probability of Free of Loss of Locomotion in the Last Time Interval Up to 2 Years (Week 106) Based on GMFC-MLD for SHP611 Group A and GLIA-MLD Matched External ControlTime frame: Baseline up to Week 106

Locations

30 sites in 14 countries. Site status is shown where the registry gives one.

  • Los Angeles Biomedical Research Institute at Harbor-UCLA

    Torrance, California

  • Childrens Hospital Colorado

    Aurora, Colorado

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Iowa Stead Family Children's Hospital

    Iowa City, Iowa

  • Mayo Clinic - PPDS

    Rochester, Minnesota

  • New York University Langone Medical Center

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Utah

    Salt Lake City, Utah

  • Hospital Universitario Austral - PIN

    Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina

  • UZ Antwerpen

    Edegem, Belgium

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Brazil

  • Stollery Children's Hospital University of Alberta

    Edmonton, Alberta, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Hospital for Sick Children

    Toronto, Ontario, Canada

  • Montreal Children's Hospital

    Montreal, Quebec, Canada

  • Hôpital Bicêtre - Paris Sud

    Le Kremlin-Bicêtre, France

  • CHU Lenval

    Nice, France

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Attikon University General Hospital

    Chaïdári, Attica, Greece

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN

    Roma, Italy

  • Kanazawa University Hospital

    Kanazawa, Japan

  • VU Medisch Centrum

    Amsterdam, Netherlands

  • Hospital Vall d'Hebrón

    Barcelona, Spain

  • Hospital Universitario Cruces

    Barakaldo, Vizcaya, Spain

  • Birmingham Children's Hospital NHS Foundation Trust

    Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.